Trial Profile
A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Lintuzumab Ac-225 (Primary) ; Mitoxantrone (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2023 Planned primary completion date changed from 1 Oct 2024 to 20 May 2024.
- 07 Sep 2023 According to an Actinium Pharmaceuticals media release, data from this study were presented at the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting.
- 07 Sep 2023 Results presented in an Actinium Pharmaceuticals Media Release.